RedVault Biosciences has been awarded a Phase I, Small Business Innovation Research grant from the National Cancer Institute to assess the utility of its advanced diagnostics technology in the early detection, stratification, and monitoring of pancreatic cancer. This technology leverages elements of molecular, genomic and synthetic biology to achieve rapid, cost-effective, and convenient analysis of clinically-relevant, cell-free miRNA populations. RedVault will use this funding to demonstrate critical feasibility and prepare this technology for more rigorous clinical application.  

External link opens in new tab or windowAdditional information on the grant, titled Digital Analysis of Plasma miRNA Populations in Pancreatic Cancer, can be found at NIH Reporter.

© 2016 RedVault Biosciences.  All rights reserved.                                                                                                                          

External link opens in new tab or windowTerms of use